International experience in implementing the strategy of sustainable development by leading pharmaceutical companies

S. G. Moroz, R. V. Sahaidak-Nikityuk, D. R. Zoidze


Aim. To study international experience in implementing sustainable development strategies by pharmaceutical companies, identifying key elements of their strategies and mechanisms to achieve sustainable development goals.

Results. Sustainable development, which involves a balanced interaction of economic, social and environmental factors, is defined by the UN as a basis for the formation of strategies at macro, meso and micro levels. It has been investigated that leading pharmaceutical companies of the world have for a long time laid the foundations of sustainable development as a basis for their strategy and consistently follow them. Based on the monitoring the official web pages of the pharmaceutical companies – leaders in the industry ranking of the Dow Jones index – it has been found that they pay significant attention to sustainable development, highlighting a separate section on the sites and systematically publishing sustainable development reports (non-financial reports). The main purpose (mission) of such companies is integrated into business processes, correlates and is clearly linked with the goals of sustainable development. Among the priorities of the business (business strategies) are especially highlighted: focus on the patient, ethics and transparency, the advantage in science, the protection of the environment. All mechanisms for implementing the strategy of sustainable development are coordinated and aimed at realization of specific goals of sustainable development: development of innovative medicines and vaccines; improving public access to health care and drugs; protection of drug safety through pharmacovigilance; compliance with the ethical code; effective management of the environment throughout the life cycle of the drug creation of a comfortable place of work of workers and increase their qualification; ensuring gender equality in managerial positions; development of
innovations through cooperation with scientists and universities and others.

Conclusions. As the experience of leading pharmaceutical companies, compliance with sustainable development strategies enables them to improve the efficiency of activities they demonstrate higher income in the long term and are the market leaders make a huge contribution to the industry and benefit society as a whole.


pharmaceutical industry; pharmaceutical company; sustainability; sustainable development; sustainable development strategy; sustainable development goals


Balashov, A. I. (2012). Formirovanie mehanizma ustoychivogo razvitiya

farmatsevticheskoy otrasli: teoriya i metodologiya – St. Petersburg, Russia: SPbGUEF.

Tsili Stalogo Rozvitku : Ukrayina. Natsionalna dopovid. (2017). Kiev: Ministry of Economic Development and Trade of Ukraine.

Belogor’ev, A. (2011). Neft Rossii, 11, 6–9.

Beiker, Sem. (2017). Osnovnaya tsel razvitiya do 2030 goda: uspeshnyiy biznes i stabilnoe buduschee. Deloit y Tush SNH.

Thepathto 2030. Retrieved from:

Jürgen, P. (2010). Sustainability in the chemical and pharmaceutical industry – results of a benchmark analysis. The Journal of Business Chemistry.Vol.7, Iss. 2, 97–106.

Missions of the pharmaceutical industry (preservation of health and innovations in SDGs. Retrieved from:

Kliuch do dosiahnennia Tsilei Staloho Rozvytku. Corporate Social Responsibility Development Center. Retrieved from:

Robeco, S. Pharmaceuticals Companies. Retrieved from:*=%22pharmaceuticals%22]

Roche Annual Report. (2017). Retrieved from: 7b4648a5edb8/en/ar17e.pdf

Sanofi. Integratedreport. (2016). Retrieved from:

Sustainability at Astra Zeneca. Retrieved from:

Takeda Sustainable Value Report. (2017). Retrieved from:

Sontrop, M. (2014). Building a Sustainable Pharmaceutical Company. Retrieved from:


GOST Style Citations

1. Балашов, А. И. Формирование механизма устойчивого развития фармацевтической отрясли : теория и методология / А. И. Балашов. – СПб.: Изд-во СПбГУЭФ, 2012. – 160 с.
2. Цілі Сталого Розвитку : Україна. Національна доповідь. – К.: Міністерство економічного розвитку і торгівлі України, 2017. – 174 с.
3. Белогорьев, А. Зачем нужен индекс устойчивого развития? / А. Белогорьев, М. Афанасьева // Нефть России. – 2011. – No 11. – С. 6–9.
4. Бейкер, С. Основная цель развития до 2030 года: успешный бизнес и стабильное будущее / С. Бейкер. – Делойт и Туш СНГ, 2017. – 70 с.
5. Thepathto 2030. [Електронний ресурс]. – Режим доступу :
6. Jürgen, P. Sustainability in the chemical and pharmaceutical industry – results of a benchmark analysis / P. Jürgen, K. Sahr // The J. of Business Chemistry. – 2010. – Vol. 7, Iss. 2. – Р. 97–106.
7. Missions of the pharmaceutical industry (preservation of health and innovations in SDGs [Електронний ресурс]. – Режим доступу:
8. Ключ до досягнення цілей сталого розвитку [Електронний ресурс] // Центр розвитку корпоративної соціальної відповідальності. – Режим доступу:
9. Robeco Sam: Pharmaceuticals Companies [Електронний ресурс]. – Режим доступу:*=%22pharmaceuticals%22
10. Roche: Annual Report – 2017. [Електронний ресурс]. – Режим доступу :
11. Sanofi. Integratedreport – 2016. [Електронний ресурс]. – Режим доступу :
12. Sustainability at Astra Zeneca – 2018. [Електронний ресурс]. – Режим доступу :
13. Takeda Sustainable Value Report 2017. [Електронний ресурс]. – Режим доступу :
14. Sontrop, M. Building a Sustainable Pharmaceutical Company [Електронний ресурс] / Mary Sontrop // Pharmaceutical Compliance Monitor. – 2014. – Режим доступу :

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Upr. ekon. zabezp. âkostì farm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)